fda warning letters bpc-157 2023 2024 2025 issued 25 to telehealth companies for false and misleading claims about compounded GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of FDA's Overreach on Compounded Peptides
FDA's Overreach on Compounded Peptides An FDA Committee Just Voted in Favor of PeptidesDespite the Agency's Opposition FDA to weigh easing limits on unproven peptides favored by RFK Jr. and MAHA supporters PBS News Trends In FDA FY 2025 Warning Letters
Pay in 4 interest-free payments of $7.08 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6



